Who is not a good candidate for semaglutide or tirzepatide
DOI: Published online: May 1, 2025 1 Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea 2 Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea Corresponding author: Jae Hyun Bae Department of Internal Medicine, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea E-mail: [email protected] Copyright 2025 Korean Diabetes Association This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
It happens to those who have lost a significant portion of weight, whether from bariatric surgery or other therapies
By incorporating these factors into our model, we aim to provide clinicians with a more accurate and personalized tool for predicting which patients might benefit most from GLP-1 M treatment
From day 7 to day 10 the differences between control and AITC-treated seedlings were smaller than those observed during the second period, indicating that the effect of AITC on root growth persisted until day 10 but decreased over time (Supplementary Figure S2)